Wolverine Asset Management
LIMNW

Wolverine Asset Management’s Liminatus Pharma Warrants LIMNW Stock Holding History

Wolverine Asset Management’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$776 Hold
13,976
– – ﹤0.01% 1664
2026
Q2 		$1.05K Sell
13,976
-25,397
-65% -$1.75K ﹤0.01% 1580
2026
Q1 		$1.58K Sell
39,373
-23,422
-37% -$1.5K ﹤0.01% 1575
2025
Q4 		$2.2K Sell
62,795
-68
-0.1% -$7 ﹤0.01% 1534
2025
Q3 		$9.3K Sell
62,863
-40,124
-39% -$7.83K ﹤0.01% 1376
2025
Q2 		$24.7K Buy
+102,987
New +$20.2K ﹤0.01% 1291

Other funds holding LIMNW

Periscope Capital
Periscope Capital Toronto, Ontario, Canada $990M AUM 4.73% 1-Year Est. Return
Arena Capital Advisors
Arena Capital Advisors Los Angeles, California $200M AUM 6.35% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $14.8M AUM 14.32% 1-Year Est. Return

Wolverine Asset Management's LIMNW Position: Q3 2026 in Review

Wolverine Asset Management held its Liminatus Pharma Warrants (LIMNW) position steady in Q3 2026 at 13,976 shares worth $776. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

Wolverine Asset Management first reported a position in LIMNW in Q2 2025 and has held it in 6 quarters since. The position peaked at $24.7K in Q2 2025. 4 funds tracked by Wall St. Rank hold LIMNW as of Q3 2026.

  • Wolverine Asset Management held 13,976 shares of Liminatus Pharma Warrants worth $776 as of Q3 2026.
  • Wolverine Asset Management left its Liminatus Pharma Warrants share count unchanged in Q3 2026.
  • Liminatus Pharma Warrants made up ﹤0.01% of Wolverine Asset Management's portfolio in Q3 2026, its #1664 holding.
  • Wolverine Asset Management first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 6 quarters since.
  • Wolverine Asset Management's Liminatus Pharma Warrants position peaked at $24.7K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q3 2026.

Based on Wolverine Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.